Assessing Lung Function and Nanotherapeutic Delivery with Magnetic Particle Imaging

Download your whitepaper

The importance of early diagnostics and therapeutic development for Acute Respiratory Distress Syndrome (ARDS) has risen sharply since the onset of the coronavirus epidemic in late 2019. ARDS in COVID-19 infections is correlated with poorer outcomes. Despite the large number of yearly ARDS cases, there does not exist an FDA approved treatment for ARDS.

Download our whitepaper to discover the groundbreaking work in diagnostics and therapeutics using nanotechnology.